| Code | CSB-RA011656MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to tozorakimab, specifically targeting interleukin-33 (IL-33), an alarmin cytokine and member of the IL-1 superfamily. IL-33 functions as a damage-associated molecular pattern protein released during cellular stress or tissue injury, signaling through the ST2 receptor to activate type 2 immune responses. This cytokine plays a critical role in the pathogenesis of various inflammatory and allergic diseases, including asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and inflammatory bowel disease. Elevated IL-33 levels have been associated with disease severity and exacerbations in respiratory conditions.
Tozorakimab is a therapeutic monoclonal antibody designed to neutralize IL-33 activity and is currently under clinical investigation for the treatment of asthma and COPD. This biosimilar antibody provides researchers with a valuable tool for studying IL-33-mediated inflammatory pathways, investigating the mechanisms of type 2 immunity, and exploring therapeutic interventions in IL-33-driven diseases. It enables in vitro and in vivo examination of IL-33 blockade effects across various disease models.
There are currently no reviews for this product.